Generic Name: Pegfilgrastim
Study IDStudied Indication or DiseasePhaseStudy TitleSynopsis
20020715Prevent neutropenia in subjects receiving FOIL (5-fluorouracil [5-FU], oxaliplatin, irinotecan, leucovorin), FOLFOX (5-FU, oxaliplatin, leucovorin), or FOLFIRI (5-FU, irinotecan, leucovorin) for local2Chemotherapy Administered Every 2 Weeks With or Without a Single Injection of Pegfilgrastim as First- or Second-Line Treatment in Subjects With Locally Advanced or Metastatic Colon Cancer
20030156Reduce the duration of neutropenia and incidence of febrile neutropenia in breast cancer patients receiving myelosuppressive chemotherapy2A Single-arm Study Evaluating the Relative Dose Intensity of IV CMF given on Day 1 and Day 8 with Pegfilgrastim Support in Subjects with Stage I - III Breast Cancer
20030218minimize the risk of hospitalizations and chemotherapy dose reductions and delays due to myelosuppression in cancer patients with a wide array of tumor types4A Multicenter, Open-label, Phase 4 Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy
20060297Non-Hodgkin’s Lymphoma (NHL)ObservationalA Retrospective and Prospective Observational Study reviewing Supportive Care Management of NHL Patients treated with CHOP-14 or 21 (with or without Rituximab)
20060445Breast, ovarian and lung cancer4A prospective observational study of neutropenia and anaemia management in subjects with solid tumours receiving myelotoxic chemotherapy
20060458solid tumours and lymphomasObservationalProspective, non-interventional study of treatment management of chemotherapy induced neutropenia in patients with solid tumours and lymphomas
20080201Gastric CancerObservationalA Prospective, Observational Study of Neutropenia Management in Subjects Receiving Myelosuppressive Chemotherapy for the Treatment of Gastric Cancer
20080259Colorectal Cancer3A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Administered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab and Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
20110146Chemotherapy Induced NeutropeniaObservational

Study to Investigate Which Clinical Risk Factors Are Considered by Physicians When Conducting Overall Febrile Neutropenia Risk Assessments for Patients Receiving Chemotherapy With an Intermediate (10% – 20%) Febrile Neutropenia Risk

20110147Incidence and/or severity of bone pain in breast cancer2Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
20110148Effect of patient education on reported bone pain in breast cancer patients receiving adjuvant or neoadjuvant chemotherapy and pegfilgrastim2Randomized, Single-blind Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim